Craig A Jacobson, a director at $EXPE, sold 3,000 shares of the company on 11-13-2025 for an estimated $814,650. We received data on the trade from a recent SEC filing. This was a sale of approximately 8.9% of their shares of this class of stock. Following this trade, they now own 30,857 shares of this class of $EXPE stock.
$EXPE Insider Trading Activity
$EXPE insiders have traded $EXPE stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $EXPE stock by insiders over the last 6 months:
- CRAIG A JACOBSON has made 0 purchases and 2 sales selling 6,000 shares for an estimated $1,437,978.
- ROBERT J DZIELAK (Chief Legal Officer & Sec'y) has made 0 purchases and 2 sales selling 5,964 shares for an estimated $1,210,381.
- LANCE A SOLIDAY (SVP & Chief Accounting Officer) sold 852 shares for an estimated $175,412
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EXPE Hedge Fund Activity
We have seen 516 institutional investors add shares of $EXPE stock to their portfolio, and 483 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 1,801,232 shares (+24899.5%) to their portfolio in Q3 2025, for an estimated $385,013,340
- AQR CAPITAL MANAGEMENT LLC added 1,473,386 shares (+102.0%) to their portfolio in Q2 2025, for an estimated $248,530,750
- JPMORGAN CHASE & CO added 1,223,297 shares (+34.3%) to their portfolio in Q3 2025, for an estimated $261,479,733
- VALUEACT HOLDINGS, L.P. removed 838,800 shares (-75.1%) from their portfolio in Q2 2025, for an estimated $141,488,784
- AMUNDI removed 786,150 shares (-61.0%) from their portfolio in Q2 2025, for an estimated $132,607,782
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 742,380 shares (-73.5%) from their portfolio in Q3 2025, for an estimated $158,683,725
- VICTORY CAPITAL MANAGEMENT INC removed 737,245 shares (-20.4%) from their portfolio in Q3 2025, for an estimated $157,586,118
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EXPE Analyst Ratings
Wall Street analysts have issued reports on $EXPE in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Argus Research issued a "Buy" rating on 11/10/2025
- Goldman Sachs issued a "Buy" rating on 11/07/2025
- Evercore ISI Group issued a "Outperform" rating on 11/07/2025
- Benchmark issued a "Buy" rating on 11/07/2025
- BTIG issued a "Buy" rating on 11/06/2025
- B. Riley Securities issued a "Buy" rating on 08/08/2025
To track analyst ratings and price targets for $EXPE, check out Quiver Quantitative's $EXPE forecast page.
$EXPE Price Targets
Multiple analysts have issued price targets for $EXPE recently. We have seen 22 analysts offer price targets for $EXPE in the last 6 months, with a median target of $260.0.
Here are some recent targets:
- Ronald Josey from Citigroup set a target price of $281.0 on 11/11/2025
- John Staszak from Argus Research set a target price of $300.0 on 11/10/2025
- Shyam Patil from Susquehanna set a target price of $265.0 on 11/10/2025
- Brad Erickson from RBC Capital set a target price of $260.0 on 11/07/2025
- Thomas Champion from Piper Sandler set a target price of $250.0 on 11/07/2025
- Mark Mahaney from Evercore ISI Group set a target price of $350.0 on 11/07/2025
- Eric Sheridan from Goldman Sachs set a target price of $295.0 on 11/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
